Bellerophon and FDA Agree on Design of Ph IIb trial of InoPulse for Pulmonary Hypertension Associated with COPD

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH)  announced on 5/8/18 that, following the receipt of minutes from a recent meeting with the U.S. Food and Drug Administration (FDA), the Company has reached agreement with FDA on all key aspects of its planned Phase 2b study of INOpulse for the treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease (PH-COPD).